Slide 1: Investor Update FY22 Annual Results
Investor Update FY22 Annual Results August 2022 Authorised for release by the Chairman and CEO
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation, being 20 July 2022. Microba may i
Slide 3: Company Snapshot
Company Snapshot Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Illumina (NASDAQ: ILMN), Genova Diagnostics, and G42 3 key therapeutic programs World-leading technology Globally leading
Slide 4: FY22 Financial Highlights
FY22 Financial Highlights (All figures in AU$) 59% 25% growth on PCP growth YoY QTR Revenue FY Revenue Q4 FY22 revenue totalled $1.86m, FY22 unaudited revenue totalled $4.69m, a record result another year of positive growth 4
Slide 5: Testing Services - Key milestones
FY22 Testing Services - Key milestones 5
Slide 6: Testing Services - Key FY22 Milestones
Testing Services - Key FY22 Milestones USA OPERATIONS GCC OPERATIONS COMMENCED COMMENCED Distribution partnership Distribution partnership to open US Healthcare to open Middle East market commenced market commenced NEW PRODUCT PARTNERSHIP LAUNCHED SIGNED Next generation Partnership signed to healthc
Slide 7: Genova Diagnostics US Distribution Partnership
Genova Diagnostics US Distribution Partnership Driving US expansion and revenue growth • Founded in 1986 • Headquartered in North Carolina • Leading gastrointestinal pathology company in the US • Genova provides GI testing solutions across all 50 states in the US. • Developed the most popular existi
Slide 8: Growing pipeline
Growing pipeline High quality new distribution partnership opportunities >20 9 3 Active leads Qualified opportunities Progressing to draft terms Prospect 1 Prospect 2 Reach into >30 countries >50k staff Sells a leading GI testing product to Reach into >50 countries healthcare practitioners a
Slide 9: Expanding network of global distribution partners
Expanding network of global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba’s world leading Analysis Platform technology. Update kit Update kit AU & NZ Europe US Middle East AU New New • Metagenics is a l
Slide 10: Therapeutics - Key milestones
FY22 Therapeutics - Key milestones 10
Slide 11: Therapeutics - Key FY22 Milestones
Therapeutics - Key FY22 Milestones Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I LEADS DISCOVERED COMMENCED IBD program lead candidate Cancer program accelerated, Autoimmune program with MAP315 progressed in ahead of schedule with Ginkgo Bioworks commence
Slide 12: Inflammatory Bowel Disease program – MAP315
Inflammatory Bowel Disease program – MAP 315 Addressing a key gap in existing therapy for UC sufferers Ulcerative Colitis Addressable Ulcerative Colitis Therapeutic Patient Population1 Global Market Size2 MAP315 has the potential to (% of total) Mild Moderate Severe ($USD Billion) 10.8 provide novel
Slide 13: Inflammatory Bowel Disease program – MAP315
Inflammatory Bowel Disease program – MAP315 Rapidly progressing to Phase I Completed Ongoing Upcoming In vivo efficacy Immunomodulation Mechanism of Action IBD UC Gut barrier integrity Data Driven UC Clinical Studies Identification MAP 315 Manufacturability cGMP Clinical Supply Lead candidate Deve
Slide 14: IFF Allergy Treatment Partnership
IFF (NYSE: IFF) Allergy Treatment Partnership Discovering novel microbiome treatments for allergies • International Flavors & Fragrances Inc. (NYSE: IFF), $29B1 market cap • Industry leader in food, beverage, health, biosciences • Major global probiotics supplier Allergy Treatment Market2 Microba ha
Slide 15: Outlook
Outlook MiCROBA
Slide 16: Outlook
Outlook Global testing • Driving sales growth with recently commenced partnerships services growth • Expansion through onboarding new partnerships • Advancing the company’s key therapeutic programs Therapeutic • Moving lead MAP315 asset into the clinic advancement • Progressing towards pivotal data
Slide 17: Appendix Microba Overview
Appendix Microba Overview 17
Slide 18: Microba's Commercial Model
Microba’s Commercial Model Global testing services build a proprietary databank driving transformative novel therapies Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven therapeutics and data
Slide 19: Microba Technology
Other Microba Technology Technology World-leading microbiome analysis technology unlocks routine testing and microbiome therapies up to 95% coverage1 up to 34x more accurate2 Published in 1 Calculated by analysing more than 10k samples across Microba’s databank Illustrative visualisation of the gast
Slide 20: The gut microbiome plays a key role in health & disease
The gut microbiome plays a key role in health & disease What is the gut microbiome? Modifying the The community of microorganisms that inhabit gut microbiome; the lower digestive tract containing trillions of microbial cells known as the gut microbiome. a key missing piece to resolving Unhealthy Hea
Slide 21: Microbiome science is changing medicine
Microbiome science is changing medicine and will transform chronic disease management Microbiome therapy to treat Microbiome testing to match patients chronic diseases with the right treatment Microbiome modulating primary and adjuvant Microbiome biomarkers and signatures are being therapies are cur
Slide 22: Large, unique, proprietary databank
Large, unique, proprietary databank driving multiple therapeutic opportunities Revealing disease signatures Already producing novel therapeutic leads across 18 diseases Proprietary Depression Parkinson’s Disease Databank 18 16 Diseases 15K 1.2M 11.7M 13 13 samples genomes genes Overweight or Obese T
Slide 23: Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monoclonal bacterial cell dr
Slide 24: Repeatable human first, data-driven therapeutic platform
Repeatable human first, data-driven therapeutic platform Demonstrating rapid translation from data to first in human CANDIDATE SELECTION PROCESS 25 bacteria 4,784 Bacteria observed Many bacteria differentially prioritised based in Microba dataset abundant in health vs IBD on signal strength 18 month
Slide 25: New strategic partnership to deliver consumer health service
New strategic partnership to deliver consumer health service • Strategic partnership with nib-backed digital healthcare company Midnight Health • Subscription model • Personalised supplements delivered monthly based on microbiome test results – delivered with trained, registered pharmacists Subscrib
Slide 26: Board of Directors
Board of Directors Pasquale Rombola Prof. Ian Frazer Dr Caroline Popper Prof Gene Tyson Dr Hyungtae Kim Richard Bund Chairman Deputy Chairman and Non-Executive Co-Founder, Non-Executive Director Non-Executive Director Non-Executive Director Chair Medical Advisory Board Director Non-Executive Directo
Slide 27: Medical Advisory Board
Medical Advisory Board Prof. Ian Frazer Dr Jakob Begun Dr Paul Griffin Dr Chris Hogan Prof Maria Abreu Prof Jean-Frederic Colombel Deputy Chairman and Medical Advisory Board, Medical Advisory Board, Medical Advisory Board, IBD Advisory Panel Member, IBD Advisory Panel Member, Chair Medical Advisory
Slide 28: Contact
Contact Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com